Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 1093

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 1093
---
 or sales made through a market maker other than on an exchange or other similar offerings through sales agents; |

| • |     | in privately negotiated transactions; |

| • |     | in options transactions; |

| • |     | through a combination of any of the above methods of sale; or |

| • |     | any other method permitted pursuant to applicable laws. |

There can be no assurance that the Selling Stockholders will sell all or any of the shares offered by this prospectus. In addition, any shares that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus. The Selling Stockholders have the sole and absolute discretion not to accept any purchase offer or make any sale of shares if they deem the purchase price to be unsatisfactory at any particular time. Subject to the terms of the agreement(s) governing the registration rights applicable to a Selling Stockholder’s shares of Common Stock, such Selling Stockholder may transfer shares of Common Stock to one or more “permitted transferees” in accordance with such agreements and, if so transferred, such permitted transferee(s) will be the selling beneficial owner(s) for purposes of this prospectus. Upon being notified by a Selling Securityholder that it intends to sell our securities, we will, to the extent required, promptly file a supplement to this prospectus to name specifically such person as a Selling Stockholder. With respect to a particular offering of the shares held by the Selling Stockholders, to the extent required, an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement of which this prospectus is part, will be prepared and will set forth, to the extent required, the following information:

| • |     | the specific shares to be offered and sold; |

| • |     | the names of the Selling Stockholders; |

| • |     | the respective purchase prices and public offering prices, the proceeds to be received from the sale, if any, and other material terms of the offering; |

| • |     | settlement of short sales entered into after the date of this prospectus; |

| • |     | the names of any participating agents, broker-dealers or underwriters, if not already named herein; and |

| • |     | any applicable commissions, discounts, concessions and other items constituting compensation from the Selling Stockholders. |

In connection with distributions of the Resale Shares or otherwise, the Selling Stockholders may enter into hedging transactions with broker